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The mammalian p38 mitogen-activated protein kinases (MAPKs) family is composed of four members (p38α,p 3 8 β,p 3 8 γ,a n d
p38δ), which are very similar in amino acid sequence but diﬀer in their expression patterns. This suggests that they may have
speciﬁc functions in diﬀerent organs. In the last years most of the eﬀort has been centred on the study of the function of the p38α
isoform,whichiswidelyreferredtoasp38intheliterature.However, therolethatotherp38isoformsplayincellularfunctionsand
their implication in some of the pathological conditions have not been precisely deﬁned so far. In this paper we highlight recent
advances made in deﬁning the functions of the two less studied alternative p38MAPKs, p38γ and p38δ. We describe that these
p38MAPKs show similarities to the classical p38α isoform,although they may play central and distinct role in certain physiological
and pathological processes.
1.Introduction
To preserve the homeostasis and health of the organism cells
are constantly responding to changes in the physical and
chemical properties of the environment by altering many of
their cellular functions. The activation of Mitogen Activated
Protein Kinases (MAPKs) is involved in the transduction of
most extracellular signals, and it is one of the major signal
transduction mechanism by which the cell adapts to changes
in the surrounding medium. In mammalian cells there are
four well-characterised MAPK families: ERK1/2, ERK5,
JNK, and p38MAPK, which are serine/threonine kinases that
catalyze the reversible phosphorylation of proteins.
The p38MAPK family comprises four members, p38α,
p38β,p 3 8 γ, and p38δ. The isoform p38α was identiﬁed in
1994 by four groups as a 38kDa polypeptide that is activated
in response to endotoxin treatment, cell stress, or cytokines
[1]. Two to three years later, three additional isoforms were
described: p38β [2–4], p38γ [5, 6], and p38δ [7, 8]. These
kinases share highly similar protein sequences; p38α and
p38β are 75% identical, whereas p38γ and p38δ are 62%
and 61% identical to p38α,r e s p e c t i v e l y .I nt u r n ,p 3 8 γ,a n d
p38δ are ∼70% identical to each other. The four p38MAPK
isoforms are widely expressed, although p38β,p 3 8 γ and
p38δ expression appear to be higher in speciﬁc tissues;
for example, p38β is abundant in brain, p38γ in skeletal
muscle, and p38δ in endocrine glands [1, 9]. In general, all
p38MAPKs are strongly activated by a wide variety of envi-
ronmental and cellularstressesor by inﬂammatory cytokines
and are poorly activated by serum or growth factors [1]. The
p38MAPK family can be further divided into two subsets
based on sequence homology, substrate speciﬁcities, and
sensitivity to chemical inhibitors, with p38α and p38β in one
group and p38γ and p38δ in the other. In this paper, we
provide an overview of the less known p38MAPK isoforms,
the p38γ and p38δ MAPK pathways, which are strongly
activated by stress, but also play important roles in tissue
regeneration, diﬀerentiation, metabolic diseases, and cancer.
2. GeneralFeaturesof p38γ andp38δ MAPKs
Human p38γ andp38δ isoformsareserine/threonineprotein
kinaseof367and365aminoacidswithapredictedmolecular
massof42–45kDaandareencodedbydiﬀerentgeneslocated
on chromosomes 22q13.3 and 6p21.31, respectively [1, 7,
10]. p38γ is also known as ERK6, SAPK3, and MAPK12. It2 Journal of Signal Transduction
was ﬁrst described by three independent studies as either
a MAPK involved in myoblast diﬀerentiation [5], a stress-
activated protein kinase (SAPK) highly expressed in skeletal
muscle [6], or a new member of the p38MAPK family [11].
p38δ, also known as SAPK4 and MAPK13, was cloned as
the fourth member of the p38MAPK family by two diﬀerent
groups [7, 8].
The structure of doubly phosphorylated, active p38γ in
complex with an ATP analog has been determined by X-ray
crystallography [12] .T h eg l o b a ls t r u c t u r eo fp 3 8 γ is similar
to other enzymes of the MAPK family and is characterized
by two domains separated by a deep channel where potential
substratesmightbind.Theduallyphosphorylatedp38MAPK
goes through characteristic global conformational changes
thataltersthealignmentofthetwokinasehalves(N-terminal
and C-terminal domains) of the folded protein and enhances
access to substrate. In addition, the interaction between
MAPKsandtheirupstreamactivatorsseemstoworkalloster-
ically to make the MAPKs activation loop available for pro-
cessing by kinases and phosphatases, which further increases
enzymatic activity [12–14]. Although the conformation of
p38γ activation loop is almost identical to that observed
in the structure of activated ERK2, contrary to ERK2, the
crystal structure of activated p38γ exists as a monomer,
suggesting that not all activated MAPKs form dimers [12].
A feature that makes p38γ unique among other MAPKs
is its short C-terminal sequence-KETXL, an amino acid
sequence which docks directly to PDZ domains of proteins,
such as α1-syntrophin, SAP (synapse-associated protein)
90/PSD (postsynaptic density) 95 and SAP97/hDlg (human
disc large), and phosphorylation of these proteins by p38γ is
dependent on its binding to the PDZ domains [15–17].
The information about p38γ and p38δ biological role
is limited compared to the extensive knowledge of p38α
and p38β functions. This is at least in part due to the
lack of speciﬁc inhibitors for p38γ and p38δ. In vitro and
in vivo assays demonstrated that only p38α and p38β are
inhibitedbycertaincompounds,suchasSB203580andother
pyridinyl imidazoles, whereas p38γ and p38δ are completely
unaﬀected by these drugs [7, 18, 19]. This is mainly due to
the diﬀerences, between p38γ and p38δ compared to p38α
and p38β, in the amino acid sequence of the ATP-binding
pocket, the site where most protein kinase inhibitors bind
and directly compete with ATP [1].
3. Regulation of p38γ andp38δ
The canonical activation of p38MAPKs occurs via dual
phosphorylation of tyrosine and threonine residues in a
conserved TGY motif, located in the activation loop of
kinase subdomain VIII. MAPK phosphatases reverse this
phosphorylation and return the p38MAPK to their inactive
state. Phosphorylation of p38MAPKs is catalysed by the
dual speciﬁcity kinases (MKK or MAP2Ks), MKK3 and
MKK6, which are in turn activated upon phosphorylation
of serine/threonine residues by phosphorylation by a MAPK
kinase kinase (MAP3K) (Figure 1). The MAP3K responsible
for activating the p38MAPK pathways appears to be cell type
and stimulus speciﬁc. Several MAP3Ks have been implicated
in the regulation of p38MAPK signalling, these include
MLKs (mixed-lineage kinases), ASK1 (apoptosis signal-
regulating kinase-1), TAO (thousand and one amino acid) 1
and 2, TAK1 (TGF β-activated kinase 1), and some members
of the MEKK (MAPK/ERK kinase kinase) family [20].
The diversity of MAP3Ks and their ability to activate also
other MAPKs provide a mechanism to respond to many
stimuli and to integrate diﬀerent signalling pathways. It has
been shown that MAP3K of the p38MAPK pathway are
regulated by binding to low molecular weight GTP-binding
proteins,ubiquitinationorphosphorylationbySTE20family
members [1, 20].
MKK3andMKK6arehighlyselectiveforp38MAPKsand
do not activate other MAPKs [1]. The major MKK required
for the activation of speciﬁc p38MAPK may be determined
byseveralfactors:oneisthecelltypeasthelevelofexpression
varies [21, 22]; another is the nature and also the strength
of the stimuli. Since MKK6 can activate all p38 isoforms in
vitro, it has been suggested that the pattern of downstream
p38MAPK activation in the particular response may be
determined by the level of MKK6 activity triggered by a
given stimulus [23]. Moreover, there are two important
structural requirements for selective activation of p38MAPK
isoforms by MKKs: docking sequences in the N-terminus of
the MKK and isoform-speciﬁc sequences of the p38MAPK
isoformswithintheactivationloop[13,24,25].UsingMKK-
targeted gene disruption and small interfering RNA (siRNA)
approaches, it has been shown that, in response to most
stimuli, MKK3 and MKK6 are the main p38α activators but,
in some circumstances, such as ultraviolet radiation, MKK4,
an activator of JNK, may contribute to p38α activation
[26]. Moreover, although it has been shown that in vitro
experiments MKK4 also phosphorylates and activates p38γ
and p38δ [7, 27], studies utilizing mouse embryonic ﬁbrob-
lasts lacking MKK3 and/or MKK6 indicate that activation
of distinct p38MAPK isoforms is regulated by the selective
and synchronized action of the two MKKs, in response to
cell stress. Thus, both MKK3 and MKK6 are essential for
p38γ activation induced by environmental stresses, whereas
MKK6isthemajorp38γ activatorinresponsetothecytokine
tumournecrosisfactor-α(TNFα).Ontheotherhand,MKK3
is the major kinase responsible for p38δ activation by
ultraviolet radiation, hyperosmotic shock, TNFα or by the
protein synthesis inhibitor anisomycin (Figure 1)[ 17]. Sup-
porting this is the ﬁnding that endogenous p38δ activation
in response to TGFβ1 is impaired in glomerular mesangial
cells from MKK3-deﬁcient mice [22]. Nonetheless, the
relative contribution of MKK3 and MKK6 to p38γ and p38δ
activation might strongly depend not only on the nature and
strength of the stimulus, but also on the cell type.
The magnitude and duration of p38MAPK signal trans-
duction are critical determinants of its biological eﬀects.
Termination of p38 kinase catalytic activity involves the
activity of several phosphatases that target the activation
loop threonine and tyrosine residues. In mammalian cells
there are good in vivo pieces of evidence for p38α activity
downregulation by several protein phosphatases, including
protein serine/threonine phosphatases (PPs) [28, 29], pro-
tein tyrosine phosphatases (PTPs) [30], and dual-speciﬁcityJournal of Signal Transduction 3
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Figure 1: The p38MAPK pathway. p38γ and p38δ MAPK substrates identiﬁed so far are shown.
phosphatases (DUSPs, also known as MAPK phosphatases
(MKPs)) [31]. However, their role in p38γ and p38δ
dephosphorylation has not been extensively studied, and
therefore very little is known about physiological p38γ and
p38δ protein phosphatases. Recently, it has been shown
in one study that p38γ interacts through its C-terminal
binding PDZ motif with the single PDZ domain of the
protein tyrosine phosphatase PTPH1. Moreover, PTPH1
can dephosphorylate p38γ,b u tn o tp 3 8 α, in vitro and in
overexpression experiments in cells. This speciﬁcity seems
to be determined by both p38γ C-terminal PDZ-binding
sequence and the conserved TGY motif within the kinase
subdomain [32].
4. p38γ andp38δ Substratesand
Biological Functions
p38MAPKfamilymembershaveoverlappingsubstratespeci-
ﬁcities, and the genetic ablation of speciﬁc p38MAPK family
members has also demonstrated the existence of functional
redundancy [16]. However, there are some diﬀerences, with
particular substrates being better phosphorylated by p38α
and p38β than p38γ and p38δ or vice versa. For example,
MAPK-activated protein kinase 2 (MK2) and MK3 are
very good substrates for p38α and p38β, but cannot be
phosphorylated by other p38MAPK isoforms [1].
The lack of speciﬁc inhibitors for p38γ and/or p38δ has
slowed down the identiﬁcation of their in vivo substrates
andtheelucidationoftheirbiologicalroles.Nonetheless,this
problem can be partly solved by the use of p38 knockout
mousemodels.p38γ andp38δ anddoublep38γ/p38δ knock-
out mice have been generated, which are viable and fertile
[16]. Moreover, the diaryl urea compound BIRB796 is not
only a potent inhibitor of p38α and p38β, but also inhibits
p38γ and p38δ at higher concentrations in cell-based assays
providing a new tool for identifying physiological roles of
these two p38MAPK isoforms [19, 33].
Several physiological substrates for p38γ MAPK isoform
have been described in the past years (Figure 1). A feature
that makes p38γ unique among all MAPKs is its short
C-terminal sequence ideal for binding PDZ domains in
proteins. p38γ binds to the PDZ domain of a variety of
these proteins, such as α1-syntrophin, SAP90/PSD95, and
SAP97/hDlg, and under stress conditions is able to phos-
phorylate them and modulate their activity [15–17]. One
valuable tool used in the identiﬁcation of p38γ substrates has
been the cell permeant peptide TatSAPK3C which contains
the last nine residues of p38γ fused to the cell-membrane
transduction domain of the human immunodeﬁciency
virus-type 1 (HIV-1) Tat protein. This peptide blocks the
phosphorylation of PDZ domain-containing proteins by
p38γ in intact cells by preventing the association of the
kinase with the PDZ domain of the substrate [16, 17].
These PDZ domain-containing proteins are scaﬀold proteins
usually targeted to the plasma membrane cytoskeleton at
specialised sites such as the neuromuscular junction and gap
junctionsthroughprotein-proteininteractions.Inthecaseof
SAP97/hDlg its phosphorylation by p38γ provides a mech-
anism of dissociating it from the cytoskeleton [16], which
indicates a role of this p38MAPK isoform in modulation
of cytoskeletal organization. SAP97/hDlg is the mammalian
homologue of the Drosophila tumour suppressor Dlg, a scaf-
foldproteinthatformsmultiproteincomplexeswithavariety
of proteins and is targeted to the cytoskeleton by its associa-
tion with guanylate kinase-associated protein (GKAP). The
p38γ-catalysed phosphorylation of SAP97/hDlg triggers its
dissociation from GKAP and therefore releases it from the
cytoskeleton (Figure 2). This is likely to regulate the integrity4 Journal of Signal Transduction
of intercellular complexes, cell shape, and volume as an
adaptive mechanism to changes in the environment [16].
SAP97/hDlg also localizes in the nucleus where it forms
a complex with the proteins polypyrimidine tract-binding
(PTB) protein-associated splicing factor (PSF) and p54nrb,
and with various RNAs, [34]. PSF and p54nrb are nucleic
acid-binding proteins that associate in vivo and regulate
transcription, pre-mRNA processing, nuclear retention of
defective RNA, as well as DNA unwinding and repair [35].
p38γ regulateshDlg-PSFcomplexdissociation inthenucleus
independently of hDlg phosphorylation by displacing PSF
from hDlg, since both proteins, p38γ and PSF, bind to PDZ1
of hDlg [34]. p38γ accumulates in the nucleus after hyper-
osmotic stress (Figure 2), but not following other p38γ-
activating stimuli such as UV irradiation. This indicates that
the nature of the stimulus determines p38γ distribution
and that some signals could release p38γ from docking
molecules that retain it in the cytosol. Moreover, the nuclear
accumulation of p38γ might be a response mechanism to
some stimuli facilitating phosphorylation of p38γ targets
in the nucleus. A nuclear role for p38γ, including func-
tional interaction with SAP97/hDlg, would not exclude its
distinct cytoplasmic role in modulating the SAP97/hDlg-
cytoskeleton complex. Indeed, through its ability to shuttle
between cytoplasm and nucleus, p38γ-SAP97/hDlg might
provide a connection between two processes critical for
adaptation to environmental changes: gene expression and
cytoskeletal reorganization.
p38γ regulation of the SAP97/hDlg-PSF complex is inde-
pendentofitskinaseactivity.Thishasbeenshownusingcells
from knockin mice expressing an endogenous inactive p38γ
mutant in combination with cells from mice lacking p38γ
[34]. Similarly, experiments in rat intestinal epithelial cells
also suggest a phosphorylation-independent role for p38γ
in K-Ras transformation, although the precise mechanism
for this regulation remains unknown [36]. p38MAPKs act
normally by direct phosphorylation of substrates on serine
or threonine residues followed by proline. However, there
are few examples showing that mammalian p38α-a n d
yeast p38MAPK-related proteins such as Spc1 or Hog1 may
also have kinase-independent roles (reviewed in [9]). Like
p38α,p 3 8 γ seems to have a kinase-independent function by
associating to protein targets and modulating their function
in the absence of phosphorylation.
p38γ substratesthatdonotrequirePDZdomain-binding
interactions are the mitochondrial protein Sab [37] and the
transcription factor MyoD, whose phosphorylation by p38γ
results in a decrease in its transcriptional activity [38].
Some p38δ substrates are proteins involved in the
regulation of microtubule dynamics, suggesting that this
p38MAPK may play a role in cytoskeletal remodelling.
Thus, the protein stathmin and the neuronal microtubule-
associated protein Tau are phosphorylated by p38δ in vitro
and in transfected cells [39–42]. Tau function is modulated
by phosphorylation, and its ability to bind and stabilise
microtubules correlates inversely with its phosphorylation
which may facilitate its self-assembly. Tau is a good in
vitro p38δ and p38γ substrate, and its phosphorylation by
these two kinases results in a reduction in its ability to
promote microtubule assembly [39, 40]. Using a siRNA ap-
proach, p38δ has been reported to be the major Tau
kinase in neuroblastoma in response to osmotic shock.
p38δ phosphorylates endogenous Tau at residue threonine-
50 (Tau-T50), which is phosphorylated in ﬁlamentous Tau
from Alzheimer’s disease brain. It seems that Tau-T50 phos-
phorylation is an early event after p38δ activation. Surpris-
ingly, this phosphorilation causes an increase in the ability
of Tau to promote microtubule assembly and help to the
adaptive response of neurons to osmotic shock, whereas
subsequent Tau phosphorylation at additional sites by p38δ
or/and by other protein kinase(s) may then instead induce
the detachment of Tau from the microtubule and destabilize
the microtubule network [39].
Finally, it has been shown that p38δ phosphorylates and
inactivates the eukaryotic elongation factor 2 (eEF2) kinase
and the protein kinase D1 (PDK1) [43–45]. PDK1 controls
insulinexocytosisinpancreaticbetacells,whichsuggeststhat
p38δ plays a role in the regulation of insulin secretion [45].
5. Physiological Roles of p38γ andp38δ
MAPK Pathways
Evidence from a number of studies carried out during the
past few years suggests that many physiological functions of
the p38MAPK isoforms may overlap but may not necessarily
be redundant and/or identical [10]. Thus, during the last few
years,studiesusingknock-outmicehaveprovidedimportant
information concerning p38γ- and p38δ-functions in vivo.
Contrary to p38α, whose constitutive deletion causes death
during embryonic development [46–48], p38γ and p38δ
deﬁcient mice are viable and have not apparent phenotype
[16]. Functional redundancy of all four p38MAPKs may
contribute, at least in part, to the lack of evident phenotype
of p38γ- and p38δ-deﬁcient mice. Nonetheless, there are
recent reports showing the implication of p38γ and p38δ in
tissue regeneration, cancer, and metabolic diseases, further
strengthening the interest of these pathways for the devel-
opment of new therapeutics strategies. Thus, p38δ seems
to be a regulator of processes related to the pathogenesis of
diabetes, such as insulin secretion and β cells death. p38δ-
deﬁcient mice have improved glucose tolerance as a result of
enhancedinsulinexocytosisbypancreaticβ cells.Correlating
with this, p38δ-deﬁcient mice show higher levels of active
PKD1, which is known to positively regulate secretion
in neuroendocrine cells, as a result of the lack of p38δ-
mediated inhibitory phosphorylation. In addition, p38δ has
been suggested as a potential therapeutic target for human
diabetes, since p38δ-deﬁcient mice are protected against the
insulinresistanceinducedbyahigh-fatdietandtheoxidative
stress-mediated β-cell failure [45].
Using mainly ectopic expression and knock-down model
cell lines it has been shown that p38γ and p38δ pathway
could be involved in the modulation of some processes
implicated in cellular malignant transformation, such as
proliferation, cell cycle progression, or apoptosis [1, 10, 49,
50] indicating a potential oncogenic role of these kinases
in cancer development and progression. In one study,Journal of Signal Transduction 5
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p38δ promotes the malignant phenotype of squamous cell
carcinoma by regulating cell proliferation and invasion [51].
In rat intestinal epithelial cells (IECs) and in human breast
cancer, p38γ RNA and protein expression increases during
Ras-induced transformation [36, 52]. p38γ knock-down in
IEC blocks the Ras transformation activity and results in
the signiﬁcant diminution of the oncogenic characteristics
of breast cancer cells [53–55]. Additionally, one recent study
shows that p38γ mediates Ras-induced senescence at least
partly by stimulating the transcriptional activity of p53
through direct phosphorylation; in contrast p38α appears
to regulate senescence in a p53-independent manner [56].
These results indicate that increased p38γ gene expression
is required for Ras oncogene activity but the mechanism by
which p38γ may promote Ras transformation is not clear.
Interestingly, p38δ was recently shown to mediate 12-O-
tetradecanoylphorbol-13-acetate-(TPA-)inducedepidermal
cell proliferation in mice, and mice lacking p38δ show
reduced susceptibility to the development of TPA-induced
skin carcinomas [57]. All these results indicate the oncogenic
function of p38γ and p38δ. Contrary, there is one study
that shows pieces of evidence indicating that p38γ and p38δ
have a role in the suppression of tumor development using
mouse embryonic ﬁbroblasts derived from mice lacking
p38γ or p38δ [58]. Lack of either p38γ or p38δ increases
cell migration and metalloproteinase-2 secretion, whereas
only p38δ deﬁciency impairs cell contact inhibition. In
addition,lackofp38γ inK-Ras-transformedﬁbroblastsleads
toincreasedcellproliferationaswellastumorigenesisbothin
vitro and in vivo [58]. These discrepancies between diﬀerent
studies could be due not only to the diﬀerence in the
experimental model and approaches used, but also to the
distinct nature of cell(s) and process(es) that is/are involved
in each experimental approach. Opposing roles in tumor
development have also been reported for the isoform p38α
[1, 59].
p38δ has been suggested to play an important role in
inducing keratinocyte diﬀerentiation by regulating the
expression of involucrin, which is a protein expressed
during keratinocyte diﬀerentiation [60]. p38δ expression is
detected in mouse and human epidermis [57, 61]. It has
been shown that activation of exogenously expressed p38δ
by diﬀerentiation-inducing agents correlates with increased
involucrin promoter activity in keratinocytes [61, 62]. This
occurs in a p38α/β-independent manner, and what is more,
p38γ is poorly expressed in keratinocytes [63]. More data
supporting the idea that p38δ may play a role in keratinocyte
diﬀerentiation come from a study carried out in lesional
psoriasis skin. Psoriasis is a chronic inﬂammatory skin
disorder characterised by keratinocytes hyperproliferation
and diﬀerentiation. It has been shown that the activity of
p38α,p 3 8 β, and p38δ is augmented in lesional psoriasis skin
compared with nonlesional psoriasis skin [64]. Additionally,
p38δ may have a dual role in keratinocytes contributing not
only to the diﬀerentiation process, but also to their apoptosis
in a PKCδ-dependent manner, though the exact mechanisms
by which p38δ may regulate keratinocyte diﬀerentiation or
apoptosis are still unknown [65, 66]. It is important to
notice that most of the pieces of evidence involving p38δ in
regulating keratinocyte diﬀerentiation or apoptosis are based
in overexpression experiments and require veriﬁcation using
other tools to both inhibit the activity or the expression of
diﬀerent p38MAPKs.
A possible p38δ and p38γ role in primary human eryth-
roid cells diﬀerentiation has been suggested. Analysis of
the mRNA expression pattern of each p38 isoform during
erythroid diﬀerentiation of primary human erythroid pro-
genitors shows that p38α and p38γ are expressed in early and
latestages,whereasp38δ mRNAisexpressedonlyatterminal
stages of diﬀerentiation, indicating a possible role of p38γ
in hematopoiesis and of p38δ during the terminal phase of
diﬀerentiation [67].
Since p38γ expression is very high in skeletal muscle in
comparison to other tissues, it is not surprising that it may
play a fundamental role in skeletal muscle diﬀerentiation.
Thus, endogenous p38γ protein level increases when myo-
blast diﬀerentiates into myotubes [68, 69]. Moreover, it has
been shown that overexpression of p38γ in skeletal muscle6 Journal of Signal Transduction
cells leads to diﬀerentiation from myoblast to myotubes and
that a dominant-negative mutant of p38γ prevented this
diﬀerentiation process [5]. Recently, studies in p38γ null
mice reported that p38γ plays a cardinal role in blocking the
premature diﬀerentiation of skeletal muscle stem cells, the
satellite cells that participate in adult muscle regeneration.
p38γ phosphorylates the transcription factor MyoD and
promotes MyoD association to the histone methyltransferase
KMT1A. This complex acts repressing transcription and the
premature expression of myogenin [38]. This is in contrast
with the essential role of p38α in muscle diﬀerentiation
[1, 70]. Moreover, p38γ is involved in muscle-speciﬁc
exercise-induced skeletal muscle adaptation, and it seems
to be required for the upregulation of PGC-1α (peroxisome
proliferator-activated receptor-γ (PPARγ)c o a c t i v a t o r - 1 α)
in mitochondrial biogenesis and angiogenesis in response to
exercise and nerve stimulation in mice [71].
6. Conclusion
Most of the studies to date have focused on the role of the
p38α isoform and report the implication of this p38MAPK
isoform in numerous biological and physiological processes.
However, the in vivo functions of other alternative p38
isoformsorthemolecularmechanismbywhichthesekinases
regulate particular cell processes remain largely unknown,
and several important questions remain to be answered to
address why a variety of p38MAPK isoforms is needed in
mammalian cells are: for example, (i) how the p38MAPK
isoforms are diﬀerentially activated by certain stimuli to
mediate speciﬁc nonredundant signals, (ii) the identiﬁca-
tion of speciﬁc physiological substrates and how they are
modulated by each p38 isoform, and (iii) the elucidation of
new in vivo roles. The use of a combination of genetically
modiﬁed mice, such as mouse lacking one or more p38
isoforms, tissue-speciﬁc knock-out mice, and knock-in mice
expressing inactive p38MAPK will be a powerful tool to
elucidate in vivo functions. Furthermore, high throughput
genomic and proteomic technologies will also help to answer
these questions and to generate enough knowledge that
hopefully could be translated in therapeutics strategies by
targeting the alternative, p38γ and p38δ MAPK isoforms.
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